GLP-1 analogue profile

Serum, 1ml

EDTA Blood, 1ml

Incretin mimetics or GLP-1 receptor agonists are active substances that are mainly administered subcutaneously and are used in the treatment of type 2 diabetes and increasingly in the treatment of obesity. Their effect is that they bind to the receptor of the endogenous peptide hormone glucagon-like-peptide (GLP-1), thereby promoting glucose-independent insulin secretion and sensitivity, slowing gastric emptying and increasing the feeling of satiety. In contrast to other antidiabetic drugs, there is a lower risk of hypoglycaemia, but gastrointestinal side effects such as bloating, nausea and vomiting are common. Some studies indicate an increased risk of pancreatitis during therapy with GLP-1 agonists. Monitoring of the pancreatic enzymes lipase and pancreatic amylase, whose increase may indicate pancreatitis, is suitable for therapy monitoring. The increase in adiponectin and the decrease in leptin correlate with an increase in insulin sensitivity, which provides information on the response to therapy with GLP-1 agonists and also on the cardiovascular risk. The block also includes the liver parameter GPT, creatinine for monitoring renal function and the long-term glucose marker HbA1c (glycated haemoglobin).